-
Shanghai announced that the first batch of products to pass the consistency evaluation in 2022 involved 210 product regulations
Time of Update: 2022-05-02
Attachment: List of the first batch of generic drug quality and efficacy consistency evaluation products listed on the Internet in 2022
-
In February, the pharmaceutical and biological companies were investigated by institutions, and the number of 3 reception fund companies exceeded 30
Time of Update: 2022-05-02
The record form of investor relations activities disclosed by Changchun Hi-Tech on February 21 shows that 145 institutional investors including Broadway Fund and Bosera Fund investigated the company on February 18.
-
10 batches of non-essential drugs in Yunnan Province were suspended from trading, 21 pharmaceutical companies applied for price cuts
Time of Update: 2022-05-02
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued two announcements, namely, “Announcement on the Qualification of Non-essential Drugs to Stop Trading” and “Announcement on Enterprises Applying for Price Reduction” .
, Ltd. In addition, after sorting out, the Yunnan Provincial Government Procurement Center received information from Shanghai Huilun Jiangsu Pharmaceutical Co.
-
Legend Bio's cilta-cel has been approved by the FDA for the launch of domestic CAR-T target competition
Time of Update: 2022-05-02
Among them, the autologous CD4-targeted CAR-T therapy LB1901 has passed the FDA's IND application and has started a phase I clinical trial in the United States for the treatment of adult relapsed or refractory peripheral T-cell lymphoma (PTCL) or skin T cells Lymphoma (PTCL), a product with rapid development in Legend Bio's pipeline .
-
Jiangxi Provincial Food and Drug Administration issued a notice to further strengthen the production management of Chinese herbal medicine pieces
Time of Update: 2022-05-02
In order to further improve and strengthen our province's Fresh Bamboo Lek Chinese herbal medicine pieces, ensure clinical efficacy, prevent product quality risks, and enhance the brand value of Gan-produced Chinese herbal medicine pieces, we are now in accordance with the "Pharmaceutical Administration Law of the People's Republic of China" and the "Measures for the Supervision and Administration of Drug Production", etc.
-
CD30-targeted drug Adcetris combined with chemotherapy: first-line treatment significantly prolongs survival!
Time of Update: 2022-05-02
ECHELON-1 is a randomized, open-label, international phase 3 study in adults with newly diagnosed advanced (stage III or IV) cHL to compare Adcetris combined with chemotherapy AVD (doxorubicin + vincristine) Efficacy and safety of ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) relative to the currently accepted standard-of-care regimen ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) .
-
Domestic pharmaceutical companies are attacking class 1 new drugs, and good news in this field continues
Time of Update: 2022-05-02
On February 18, Osaikang announced that the innovative drug ASKG712 injection independently developed by Suzhou Osaikang, a wholly-owned subsidiary, was approved by the State Food and Drug Administration for clinical trials.
-
Medical companies are setting off a wave of listing in Hong Kong!
Time of Update: 2022-05-02
However, it should be noted that under the background of the current medical enterprises getting together to list in Hong Kong, there are many medical companies that have failed to go public due to the expiration of their prospectus .
-
This anticoagulant drug market with sales of over 100 million has added another entrant!
Time of Update: 2022-05-02
The industry pointed out that for the generic drug of apixaban, a blockbuster product, the country is already in a situation of competition for hegemony, and it is uncertain which pharmaceutical company can win in the domestic anticoagulant market in the future .
-
Kangchen Pharmaceutical's KC1036 entered Phase Ib/II clinical study for the treatment of advanced digestive system tumors
Time of Update: 2022-05-02
On February 23, Kangchen Pharmaceutical issued an announcement saying that recently, Kangchen Pharmaceutical's "Phase Ib/II clinical study plan to evaluate the efficacy and safety of KC1036 in the treatment of advanced recurrent or metastatic digestive system tumors" was published in the Chinese Academy of Medical Sciences.
-
CDE Publishes Guidelines for Mixing Uniformity and Intermediate Control Dose Uniformity of Chemical Drug Solid Preparations
Time of Update: 2022-05-02
On February 18, the CDE official website issued an announcement stating that in order to guide the research on the mixing uniformity of chemical oral solid preparations and the uniformity of the medi
-
In 2024, the market size of autoimmune drugs may reach nearly 50 billion yuan
Time of Update: 2022-05-02
Incomplete statistics show that as of November 2021, in its R&D pipeline, in addition to the marketed TNF-α inhibitor Yisaipu, there are 5 self-immune drugs under development, 3 of which have completed clinical phase I trials.
-
Transformation of a large number of pharmacies: choose between professionalism and convenience
Time of Update: 2022-05-02
In accordance with the requirements of the Guangdong Provincial Food and Drug Administration, it will innovate the drug retail business model, lead and meet the diverse needs of community residents for 24-hour daily urgent needs for drugs, and promote the transformation of traditional pharmacies into community health convenience stores .
-
7 pharmaceutical companies including Rejing Bio announced their performance reports, and 5 companies reported good news
Time of Update: 2022-05-02
81% from the same period of the previous year; net profit attributable to shareholders of the parent company was -176 million yuan, compared with the previous year.
10% over the same period of the previous year; the net profit attributable to shareholders of the parent company was 119 million yuan, a year-on-year increase.
-
Ono Pharma's VelexbruBTK inhibitor approved in Taiwan for the treatment of adult patients with PCNSL
Time of Update: 2022-05-02
Ono Pharmaceutical recently announced that the company's BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet) has been approved in Taiwan, China for the treatment of relapsed or refractory B-cell primary central nervous system lymphoma (PCNSL) adult patients .
-
A group of pharmaceutical companies announced the completion of financing, which will be used to speed up the research and development of new products
Time of Update: 2022-05-02
(hereinafter referred to as "Qinhao Pharmaceutical") also announced that the company has completed a series B financing of several hundred million yuan .
(“Tianrui Diagnosis”), a provider of medical diagnostic service solutions, also announced the completion of the B+ round of financing of 100 million yuan .
-
The 100 billion blue ocean of the domestic pharmaceutical equipment market appears?
Time of Update: 2022-05-02
Therefore, with the emergence of a blue ocean in the domestic pharmaceutical machine market, domestic pharmaceutical machine companies also need to strengthen technological innovation, increase investment in research and development, build high-level equipment, and create strong market competitiveness .
-
After the multinational pharmaceutical company spins off its business, it will set up a new company to go public
Time of Update: 2022-05-02
In 2020, Merck announced the split plan, the tumor, in-hospital products, vaccines and animal health businesses will continue to be retained, while a new company will be established for women's health products, mature products and biosimilar products and listed independently, which is expected to be completed in the first half of 2021.
-
National Medical Insurance Bureau: The scale of direct settlement of general outpatient expenses across provinces continues to increase
Time of Update: 2022-05-02
According to the data, as of the end of January 2022, 53,800 designated medical institutions have been connected to the nationwide direct settlement of hospitalization expenses across provinces .
-
Briefly analyze the market status and prospects of eight categories of domestic pharmaceutical equipment
Time of Update: 2022-05-02
In recent years, with the upgrading of pharmaceutical consumption, the research level of new preparations has been continuously improved, and the market of new preparations in China has also continued to expand, bringing opportunities to the preparation machinery and equipment industry .
